@biotech_jack Biotech_Jack

Biotech_Jack posts on X about $abvx, $iova, data, $abbv the most. They currently have [---] followers and [---] posts still getting attention that total [---------] engagements in the last [--] hours.

Engagements: [---------] #

[--] Week [------] +53%
[--] Month [------] +151%
[--] Months [------] +2,069%
[--] Year [------] +1,523%

Mentions: [--] #

[--] Months [--] +108%
[--] Year [--] +233%

Followers: [---] #

[--] Week [---] +4%
[--] Month [---] +22%
[--] Months [---] +68%
[--] Year [---] +131%

CreatorRank: [-------] #

Social Influence

Social category influence stocks finance countries currencies travel destinations technology brands cryptocurrencies

Social topic influence $abvx #5, $iova, data, $abbv, in the, ecco, ceo, goldman sachs, $unh, strong

Top accounts mentioned or mentioned by @macrovet888 @canoebrookbl @physioo @semodough @seedy19tron @amaymd @basadomente @jackman724444 @bioinvestor24 @doepkemichel @wallstsai @btcbabey @mahasr199 @laminarred @64 @drsprs @tarrikzaid @hparkerevans @milo1001 @cloudwalker200

Top assets mentioned Abivax SA (ABVX) Iovance Biotherapeutics, Inc. Common Stock (IOVA) AbbVie Inc (ABBV) Goldman Sachs (GS) UnitedHealth Group (UNH) Ocular Therapeutix, Inc. (OCUL) Pfizer, Inc. (PFE) Viking Therapeutics, Inc (VKTX) Nov Inc (NOV) Madrigal Pharmaceuticals, Inc. Common Stock (MDGL) uniQure N.V. (QURE) BridgeBio Pharma, Inc. Common Stock (BBIO) Soleno Therapeutics, Inc. Common Stock (SLNO) Protagonist Therapeutics, Inc (PTGX) Sanofi (SNY) ShockWave Medical, Inc. (SWAV) IDEAYA Biosciences, Inc. Common Stock (IDYA) SpringWorks Therapeutics, Inc. Common Stock (SWTX) Immunogen Inc (IMGN) Insmed, Inc. (INSM) Alnylam Pharmaceuticals, Inc. (ALNY) Terns Pharmaceuticals, Inc. (TERN) Merck & Co., Inc. (MRK) T Rowe Price Group Inc (TROW)

Top Social Posts

Top posts by engagements in the last [--] hours

"$SWAV +558% 🚀🚀🚀"
X Link 2023-11-13T17:25Z [--] followers, [---] engagements

"$IOVA Iovance Biotherapeutics initiated with a Buy at Goldman Sachs ; target $12"
X Link 2023-11-20T10:18Z [--] followers, [---] engagements

"@drsprs @tarrikzaid 15.38% owned by Fresenius Medical Care AG"
X Link 2024-04-11T13:20Z [--] followers, [---] engagements

"@HParkerEvans A typical Viagra chart but that's what happens when $PFE rumours arise. $VKTX"
X Link 2024-08-19T19:20Z [--] followers, [---] engagements

"$IDYA $IDYA Q3: $1.2b cash. Darovasertib trial ahead of schedule. FDA meeting successful. IDE397 combo study ongoing. IDE275 IND cleared. Funded into [----]. https://t.co/jPgktfatwC $IDYA Q3: $1.2b cash. Darovasertib trial ahead of schedule. FDA meeting successful. IDE397 combo study ongoing. IDE275 IND cleared. Funded into [----]. https://t.co/jPgktfatwC"
X Link 2024-11-04T11:59Z [--] followers, [---] engagements

"Is this a cup handle $IOVA $IOVA nice move https://t.co/dyUixTEHgK $IOVA nice move https://t.co/dyUixTEHgK"
X Link 2024-11-06T19:25Z [--] followers, [---] engagements

"$IOVA starter @ 9.87"
X Link 2024-11-08T15:08Z [--] followers, [---] engagements

"$IOVA analysts update 11/7&8/24 Trust Sec buy [--] $ Mizuho outperform [--] $ Stifel buy [--] $ Wells Fargo overweight [--] $ HC Wainwright buy [--] $ Jefferies buy [--] $ Guggeneim neutral TD Cowen buy Piper Sandler neutral [--] $ Chardan Capital buy [--] $ Barclays overweight [--] $"
X Link 2024-11-08T19:45Z [--] followers, [---] engagements

"@milo1001 Several thousand caught between [----] and [----]. Goldman has a price target above [--]. nice $IOVA"
X Link 2024-11-08T20:17Z [--] followers, [---] engagements

"@cloud_walker200 No government in the world can change eating habits that have existed for decades. Long $VKTX. And if they do short $MCD. .but Donald doesn't like that"
X Link 2024-11-20T19:52Z [--] followers, [---] engagements

"$NBIX CEO at $NBIX sells $9.2M (32% of their holdings and their 2nd largest sale ever) https://t.co/0xfflH8uaJ CEO at $NBIX sells $9.2M (32% of their holdings and their 2nd largest sale ever) https://t.co/0xfflH8uaJ"
X Link 2025-02-07T15:49Z [--] followers, [---] engagements

"@A_May_MD Do you like $NOV on this level Thank you for feedback"
X Link 2025-03-28T16:39Z [--] followers, [--] engagements

"@A_May_MD Yes I think so too. Chart looks crap. What do you think about license expiry in China in [----] for $NOV. Does that already play a role"
X Link 2025-03-28T16:47Z [--] followers, [--] engagements

"@haodongvli No $SWTX buyout before June [--]. 2025: In [----] there will be several significant changes to the Executive Board at Merck: New CEO Life Science: As of June [--] [----] Jean-Charles Wirth will take over the management of the Life Science division from Matthias Heinzel"
X Link 2025-04-14T18:38Z [--] followers, [---] engagements

"$UNH DOJ likely shifting $UNH lawsuit because they know they cant win as-is. https://t.co/mGIHN7XKqz DOJ likely shifting $UNH lawsuit because they know they cant win as-is. https://t.co/mGIHN7XKqz"
X Link 2025-06-26T05:44Z [--] followers, [---] engagements

"$UNH US SENATE GOP EYES DELAYING KEY MEDICAID CUT PUNCHBOWL US SENATE GOP EYES DELAYING KEY MEDICAID CUT PUNCHBOWL"
X Link 2025-06-26T10:46Z [--] followers, [---] engagements

"$MDGL $VRNA $XBI There is a very common misconception about M&A when a company announces new Credit Facility or Financing Deal Today $MDGL Madrigal Pharma announced they obtained $500 Million credit facility from Blue Owl Capital in which $350 Million is already funded and $150 Million is https://t.co/ArvxeXLocU $XBI There is a very common misconception about M&A when a company announces new Credit Facility or Financing Deal Today $MDGL Madrigal Pharma announced they obtained $500 Million credit facility from Blue Owl Capital in which $350 Million is already funded and $150 Million is"
X Link 2025-07-23T06:02Z [--] followers, [---] engagements

"@LTbioinvestor $CYBN"
X Link 2025-07-28T17:46Z [--] followers, [---] engagements

"$CYBN AbbVie in Talks to Acquire Gilgamesh in $1 Billion Deal https://t.co/gL2pnB2zVo AbbVie in Talks to Acquire Gilgamesh in $1 Billion Deal https://t.co/gL2pnB2zVo"
X Link 2025-07-31T06:11Z [--] followers, [---] engagements

"@LBR_ZA Goldman Sachs increase PT up to 19$ from 10$ / neutral"
X Link 2025-08-07T09:31Z [--] followers, [--] engagements

"$ABVX atm on 07/24/25 @64$ New shareholders Goldman Sachs [-------] shares UBS AG [-------] shares"
X Link 2025-08-14T07:18Z [--] followers, [---] engagements

"@PickingMyOwn @EggCapitalWS @A_May_MD Buyout rumours in $NKTR .would be great"
X Link 2025-08-19T11:40Z [--] followers, [---] engagements

"@DmitryKovalchuk Restrike the conversion price. From before [--------] USD to [--] USD in the nw CB"
X Link 2025-08-21T11:20Z [--] followers, [---] engagements

"@PCM_bio Ups I did it again. @ [----] in Paris"
X Link 2025-09-12T12:40Z [--] followers, [---] engagements

"@physioo Let's talk about the CMO Dr. Fabio Cataldi. Have a look on his former role in Landos and Arena Pharma. $ABVX $PFE $ABBV"
X Link 2025-09-18T14:10Z [--] followers, [---] engagements

"@doepke_michel Do you holding $KURA"
X Link 2025-10-08T17:26Z [--] followers, [---] engagements

"$ABVX ADR PT raised to $150 from $101 at Guggenheim"
X Link 2025-10-10T10:18Z [--] followers, [----] engagements

"$ABVX ABIVAX NAMED BEST IDEA AT GUGGENHEIM WITH STREET-HIGH PT $150"
X Link 2025-10-10T10:19Z [--] followers, [---] engagements

"$QURE Today Dr. Victor Sung one of the investigators in our AMT-130 #genetherapy trial gave an oral presentation on the AMT-130 topline pivotal data as part of the #HDCongress2025 HD Clinical Trials Update. #huntingtonsdisease https://t.co/5omxCmFyfT Today Dr. Victor Sung one of the investigators in our AMT-130 #genetherapy trial gave an oral presentation on the AMT-130 topline pivotal data as part of the #HDCongress2025 HD Clinical Trials Update. #huntingtonsdisease https://t.co/5omxCmFyfT"
X Link 2025-10-13T03:33Z [--] followers, [---] engagements

"Abivax ADRs rated new overweight at Barclays; PT $142 $ABVX"
X Link 2025-10-13T08:47Z [--] followers, [----] engagements

"uniQure PT Raised to $65 from $55 at RBC $QURE"
X Link 2025-10-13T08:49Z [--] followers, [---] engagements

"Can anyone confirm that $ABVX holds its own shares Bloomberg shows a holding of [-------] shares as of 10/06/25"
X Link 2025-10-14T11:11Z [--] followers, [---] engagements

"$IMGN *IMMUNOGEN SEEN AS TARGET FOR BIG BIOPHARMA: GUGGENHEIM"
X Link 2023-10-26T11:13Z [--] followers, [---] engagements

"$BBIO Cantor Fitzgerald raised target on Bridgebio Pharma Inc. to $90 from$70. Maintains overweight rating"
X Link 2025-02-20T15:22Z [--] followers, [---] engagements

"$abvx Research update Citizens 11/04/25 market outperform PT 114$ Leerlink 11/03/25 outperform PT 115$ Kempen 10/17/25 buy PT 150$ Piper Sandler 10/17/25 overweight PT 112$ Barclays 10/13/25 overweight PT [---] $ Guggenheim 10/10/25 buy PT 150$"
X Link 2025-11-04T09:12Z [--] followers, [---] engagements

"@JoseRestonVA Im with you @ [----] $SLNO"
X Link 2025-11-07T16:57Z [--] followers, [---] engagements

"$SLNO $SLNO is repurchasing $100M of its stock. Strong move. https://t.co/urev6a6Cqn $SLNO is repurchasing $100M of its stock. Strong move. https://t.co/urev6a6Cqn"
X Link 2025-11-11T12:08Z [--] followers, [---] engagements

"The "we know our way around" argument: The speaker repeatedly stresses: "We know the safety profile of Skyrizi/Rinvoq." This suggests to doctors: "Don't take any risks with the new.""
X Link 2025-12-03T20:46Z [--] followers, [---] engagements

"$ABBV is proactively trying to control the narrative before Abivax gets broad market approval (planned for around 2026). If Abivax were just a small niche product AbbVie would ignore it"
X Link 2025-12-03T20:49Z [--] followers, [---] engagements

"@semodough $PTGX"
X Link 2025-12-12T20:00Z [--] followers, [---] engagements

"$ABVX trading today"
X Link 2025-12-30T19:46Z [--] followers, [----] engagements

"$ABVX Whale multileg: Long $145C Short $90P Short $195C. Smart money bets on takeover price landing exactly between $145-$195 by Feb '26"
X Link 2025-12-31T17:05Z [--] followers, [---] engagements

"@WallStSai $ABVX Whale multileg: Long $145C Short $90P Short $195C. Smart money bets on takeover price landing exactly between $145-$195 by Feb '26"
X Link 2025-12-31T17:05Z [--] followers, [---] engagements

"@PJamess69 Only about [------] shares are needed for the crash. It sounds paradoxical but a crash shortly before the deal is extremely common"
X Link 2026-01-05T17:18Z [--] followers, [--] engagements

"$ABVX any questions"
X Link 2026-01-09T06:10Z [--] followers, [----] engagements

"$ABVX trading $ABVX trading today https://t.co/y3TixoxZD0 $ABVX trading today https://t.co/y3TixoxZD0"
X Link 2026-01-09T14:14Z [--] followers, [----] engagements

"@seedy19tron $OCUL replaced the entire C-suite in [----] just to perfect the art of the empty Corporate Day and shifting trial goalposts. Changing protocols mid-game isn't incompetence it is apparently just agile leadership while dressing up the mess for a Sanofi bailout"
X Link 2026-01-16T15:01Z [---] followers, [----] engagements

"@plainyogurt21 @seedy19tron Dugel flipped Iveric for billions but is now playing hard to get at $OCUL It must be deep "conviction"or just the inconvenient fact that his millions in options remain worthless paper until the bid hits $20 $25 and $30"
X Link 2026-01-16T17:23Z [--] followers, [---] engagements

"@basadomente Running the Bayesian model on $ABVX: The strong match in Ph2 vs Ph3 induction data implies a statistically high probability of success for Q2 maintenance. The math is bullish"
X Link 2026-01-16T17:47Z [---] followers, [----] engagements

"Crucial for Due Diligence: CMO F. Cataldi was previously Global Team Lead Gastro at AbbVie. He knows the internal data & limitations of Skyrizi/Rinvoq better than anyone. Connect the dots"
X Link 2026-01-19T09:17Z [---] followers, [----] engagements

"$ABVX Crucial for Due Diligence: CMO F. Cataldi was previously Global Team Lead Gastro at AbbVie. He knows the internal data & limitations of Skyrizi/Rinvoq better than anyone. Connect the dots. Crucial for Due Diligence: CMO F. Cataldi was previously Global Team Lead Gastro at AbbVie. He knows the internal data & limitations of Skyrizi/Rinvoq better than anyone. Connect the dots"
X Link 2026-01-20T07:05Z [--] followers, [----] engagements

"@MACROVET888 @CyclesFan In every bubble long-term investors are too impatient. That's clear. More than [--] years of stagnation and then this. I own copper. For example $NGEX.TO. HOLD STRONG"
X Link 2026-01-23T20:56Z [--] followers, [--] engagements

"@btcbabey @physioo @seedy19tron Fabio Cataldi CMO Abivax SA was previously CMO at Landos Bio. Landos Bio was successfully sold to AbbVie in [----]. Cataldi also held leadership positions at other pharmaceutical companies including Arena Pharmaceuticals (acquired by Pfizer) Shire (acquired by Takeda)"
X Link 2025-09-12T05:56Z [---] followers, [---] engagements

"$ABVX The resume of Fabio Cataldi CMO of Abivax SA shows some notable features. @btcbabey @physioo @seedy19tron Fabio Cataldi CMO Abivax SA was previously CMO at Landos Bio. Landos Bio was successfully sold to AbbVie in [----]. Cataldi also held leadership positions at other pharmaceutical companies including Arena Pharmaceuticals (acquired by Pfizer) Shire (acquired by Takeda) @btcbabey @physioo @seedy19tron Fabio Cataldi CMO Abivax SA was previously CMO at Landos Bio. Landos Bio was successfully sold to AbbVie in [----]. Cataldi also held leadership positions at other pharmaceutical companies"
X Link 2025-09-12T14:00Z [---] followers, [---] engagements

"@PersimmonTI $PTGX maybe"
X Link 2026-01-10T15:59Z [--] followers, [---] engagements

"De Garidels M&A playbook at $ABVX is clear. 2020: Sold Corvidia to Novo ($2.1bn). 2023: Sold CinCor to AZN ($1.8bn). Since May '23 he has reassembled that exact exit-focused team"
X Link 2026-01-19T09:17Z [---] followers, [----] engagements

"@realchinesespy $ABVX Deal math at 15bn: Basic (78.4m shs): [---] Fully Diluted (88m): [---] Even in the max diluted scenario the valuation floor is +70% above current price. Do the math"
X Link 2026-01-20T06:23Z [--] followers, [----] engagements

"@WallStSai "Noise" isn't a denial it's leverage. MDG played the exact same "stand-alone" card at CinCor just weeks before the $1.8bn sale. You don't dismiss 15bn unless you hold aces. $ABVX"
X Link 2026-01-20T11:46Z [--] followers, [----] engagements

"@basadomente Confirmed: $ABVX anti-fibrosis data gets the coveted 'OP30' Oral Presentation at ECCO. Validated by KOL Danese. This is the 'Holy Grail' mechanism Big Pharma must pay for"
X Link 2026-01-23T20:17Z [---] followers, [----] engagements

"ECCO Oral Pres: $ABVX Obefazimod significantly reduces fibrosis in human cells & outperforms Upadacitinib. Validates blockbuster potential beyond mere symptom management"
X Link 2026-01-23T20:36Z [---] followers, [----] engagements

"@riocybin @grok ECCO Oral Pres: $ABVX Obefazimod significantly reduces fibrosis in human cells & outperforms Upadacitinib. Validates blockbuster potential beyond mere symptom management"
X Link 2026-01-23T20:39Z [---] followers, [----] engagements

"Exactly. Rinvoq puts out the fire but $ABVX repairs the house (Anti-Fibrosis). This "Structural Repair" is the multiplier lifting the valuation from $15bn to $25bn+. @Chazthzorshte"
X Link 2026-01-23T20:54Z [---] followers, [----] engagements

"@doepke_michel @lalettre_fr Walking US bankers through French FDI control as an 'educational exercise' isn't done for standalone scenarios. The silence is regulatory discipline not a void. $ABVX"
X Link 2026-01-26T07:34Z [---] followers, [---] engagements

"@canoebrookbl Efficacy is only half the battle. Downplaying 'Black Box' risks overlooks the 1L market. There the winner often isn't the strongest drug but the safest one without a warning label. $ABVX"
X Link 2026-01-26T18:08Z [---] followers, [---] engagements

"@canoebrookbl Valid points on TL1A potency but timing is key. $ABVX is a 'now' asset hitting the sweet spot: Oral convenience + Clean Safety before TL1A arrives. Being the 'First Safe Pill' captures the massive 1L market that fears the Box regardless of eventual efficacy hierarchy"
X Link 2026-01-26T18:50Z [---] followers, [----] engagements

"@JackMan724444 @canoebrookbl Correct. 51% remission in refractory cases validates the 77% seen in bio-nave patients. Passing this stress test unlocks mass market dominance. That's the real value driver. $ABVX"
X Link 2026-01-26T19:10Z [---] followers, [---] engagements

"@canoebrookbl Patents to [----] bridge the [----] Pharma cliffs perfectly. Buyers need 'Cash Flow Now'. Also: 77% remission in bio-nave patients drives the 1L market adoption regardless of conservative initial label semantics. $ABVX"
X Link 2026-01-26T19:55Z [---] followers, [---] engagements

"@JackMan724444 @canoebrookbl Whether [----] (Base) or [----] (PTE/Method) the runway fully covers the critical ROI phase. Big Pharma buys assets not calendar years. With every patent extension the valuation shifts upwards by billions. $ABVX"
X Link 2026-01-26T20:12Z [---] followers, [---] engagements

"@bioinvestor24 Payers won't fund dual-biologic pricing for the masses. While combos chase the refractory 10% (Salvage) $ABVX locks the 1L volume via 'Oral Access'. Unit Economics beat Science Fiction"
X Link 2026-01-28T13:01Z [---] followers, [----] engagements

"@bioinvestor24 Convenience isn't just frequency it's autonomy. Patients want normalcy not needles. But the clinical ace is PK/PD: You can stop a pill instantly if an issue arises (washout). You can't simply 'turn off' a Q3M injection if an infection hits. $ABVX"
X Link 2026-01-28T13:09Z [---] followers, [----] engagements

"@bioinvestor24 Naturally AbbVie's CMO defends his book. But IBD isn't a zero-sum game. Skyrizi owns the 'Biologic Ceiling' (High End) Orals capture the 'Pre-Bio Floor' (Early Access). The thesis is market expansion via earlier intervention not just cannibalization. $ABVX"
X Link 2026-01-28T13:23Z [---] followers, [----] engagements

"@MACROVET888 @DarioCpx Very good decision short silver on Wednesday and covered today. Wait for ECCO pay the price. Big Pharma buys BEFORE the data. $ABVX"
X Link 2026-01-30T21:12Z [---] followers, [----] engagements

"@OncoRareVoice Textbook setup: Price makes lower lows momentum makes higher lows (Bullish Divergence). Add a 'Falling Wedge' and volatility compression. This signals seller exhaustion. The rubber-band snap-back is imminent. Bears are walking into a trap. $ABVX"
X Link 2026-01-31T09:54Z [---] followers, [---] engagements

"@basadomente Lilly's $3.2B Morphic bet imploded (data placebo). Their IBD pipeline hole is gaping again. $ABVX shifts from 'nice-to-have' to 'must-have'. If they paid billions for a flop the premium for quality just skyrocketed"
X Link 2026-02-01T09:31Z [---] followers, [----] engagements

"@Chazztheshort YTD: $ABVX -16.92% Like $MDGL -17.61% $ALNY -15.52% $UNH -14.71% $TERN -13.74% $INSM -11.43% Do you need more pump and dump please give me a sign. Serious advice you should buy T Bills. You're always so excited. You can relax 😴"
X Link 2026-02-02T13:25Z [---] followers, [----] engagements

"@semodough AZN's direct listing is live. Doug confirms: 'Fuel for deals & deeper US access'. Unifying structure means arming for M&A. The acquisition currency is now polished & ready to deploy for share deals. Perfect timing. $ABVX"
X Link 2026-02-02T17:46Z [---] followers, [----] engagements

"$ABVX ABIVAX Marc de Garidel Thoron a acquis des titres Abivax https://t.co/3abtDb5OU9 ABIVAX Marc de Garidel Thoron a acquis des titres Abivax https://t.co/3abtDb5OU9"
X Link 2026-02-03T10:14Z [---] followers, [----] engagements

"@MACROVET888 Tax tactics: Selling actual shares often means Capital Gains (low tax) vs Income Tax (high). De Garidel is maximizing his Net for the exit. Bags are packed for payday. $ABVX"
X Link 2026-02-03T13:37Z [---] followers, [---] engagements

"@semodough $MRK Mgmt confirms: M&A "sweet spot" is $15B open to go higher for top science. The jet just returned from Paris. $ABVX fits the exact budget & clinical profile. This isn't a coincidence it's a financial bullseye"
X Link 2026-02-04T18:37Z [---] followers, [----] engagements

"@mahasr199 @semodough That's kind of you I'm not selling any $ABVX shares"
X Link 2026-02-04T19:02Z [---] followers, [---] engagements

"$ABVX L'Obefazimod mdicament convoit par les USA 💊 "a permet de rduire les cytokines pro-inflammatoires ; il y en a plusieurs qui sont rduites dans cette maladie et qui vont baisser." 💬 Marc de Garidel directeur gnral d'Abivax https://t.co/kkFLBBOgJD L'Obefazimod mdicament convoit par les USA 💊 "a permet de rduire les cytokines pro-inflammatoires ; il y en a plusieurs qui sont rduites dans cette maladie et qui vont baisser." 💬 Marc de Garidel directeur gnral d'Abivax https://t.co/kkFLBBOgJD"
X Link 2026-02-05T09:00Z [---] followers, [----] engagements

"@LaminarRed $ABVX (ADR) T Rowe Price Group Inc +476869 shr per 02/12/26 / total [------] NN GROUP NV +514637 shr per 12/31/25 / toal [-------] shr"
X Link 2026-02-12T13:30Z [---] followers, [---] engagements

"@LaminarRed Invus (Moderna track record) reports 5% stake. Smart money of this caliber targets multiples. This position validates the valuation fundamentally and cements the floor for M&A negotiations. $ABVX"
X Link 2026-02-13T19:10Z [---] followers, [---] engagements

"$OCUL CEO Pravin Dugel brings a confirmed M&A track record previously orchestrating the $5.9bn sale of Iveric Bio to Astellas in [----]. Amid reports of a renewed bid from Sanofi this history suggests a management team experienced in navigating high-value strategic exits"
X Link 2026-01-15T12:22Z [---] followers, [---] engagements

"@MACROVET888 Rampulla (741k) & CEO De Garidel (681k) now hold 1.42M shares combined. That's 150M 'Skin in the Game'. They aren't negotiating for salary but for the maximum Exit. $ABVX"
X Link 2026-02-03T14:03Z [---] followers, [----] engagements

"$ABVX Betaville 'uncooked alrt'"
X Link 2026-02-12T13:25Z [---] followers, 11.8K engagements

"@physioo Big Pharma seeks "Deepening Remission": Obe-50 increased clinical remission from 39.8% (W8) to 67.0% (W48). This prevents secondary loss of response & maximizes long-term retention. $ABVX"
X Link 2026-02-17T08:40Z [---] followers, [----] engagements

"@biotechbeta Strategic Hire: Keith Fournier (ex-EMD Serono) leads Regulatory. This mitigates execution risks & optimizes risk-adjusted valuation for strategic bidders. Asset is 'turnkey-ready'. $ABVX"
X Link 2026-02-16T10:55Z [---] followers, [----] engagements

"$ABVX Dont miss Abivax at #ECCO2026. Were presenting [--] abstracts highlighting scientific data on obefazimod in #InflammatoryBowelDisease including new insights into its potential anti-fibrotic properties. Details: https://t.co/ugty5s7eep https://t.co/4N5w3esDUe Dont miss Abivax at #ECCO2026. Were presenting [--] abstracts highlighting scientific data on obefazimod in #InflammatoryBowelDisease including new insights into its potential anti-fibrotic properties. Details: https://t.co/ugty5s7eep https://t.co/4N5w3esDUe"
X Link 2026-02-17T14:28Z [---] followers, [----] engagements

"RT @MitchMartan98: $ABVX looking forward to these. Rumours have settled a lot of traders have moved on yet the stock is still comfortably"
X Link 2026-02-17T18:09Z [---] followers, [--] engagements

"$ABVX looking forward to these. Rumours have settled a lot of traders have moved on yet the stock is still comfortably in the $120s region. Maintenance data only a few months away now. Slow grind continues. Dont miss Abivax at #ECCO2026. Were presenting [--] abstracts highlighting scientific data on obefazimod in #InflammatoryBowelDisease including new insights into its potential anti-fibrotic properties. Details: https://t.co/ugty5s7eep https://t.co/4N5w3esDUe Dont miss Abivax at #ECCO2026. Were presenting [--] abstracts highlighting scientific data on obefazimod in #InflammatoryBowelDisease"
X Link 2026-02-17T18:07Z [----] followers, [---] engagements

"Dont miss Abivax at #ECCO2026. Were presenting [--] abstracts highlighting scientific data on obefazimod in #InflammatoryBowelDisease including new insights into its potential anti-fibrotic properties. Details: https://bit.ly/4rV6GQr https://bit.ly/4rV6GQr"
X Link 2026-02-17T12:00Z [----] followers, [----] engagements

"bro replaced the entire company with a Mac mini. 😂"
X Link 2026-02-17T11:44Z 17.1K followers, [----] engagements

"$ABVX $ABVX numbers for the 48w P2b open label maint trial are pretty remarkable. Key is using the same pt subgroup enrolled in the P3 maint trial. 77% remission in AT naive is really an imaginary number and better than SNY TL1A maint data just out. Very high confidence for P3 maint https://t.co/BeT4TXX1UU $ABVX numbers for the 48w P2b open label maint trial are pretty remarkable. Key is using the same pt subgroup enrolled in the P3 maint trial. 77% remission in AT naive is really an imaginary number and better than SNY TL1A maint data just out. Very high confidence for P3 maint"
X Link 2026-02-17T11:49Z [---] followers, [----] engagements

"$ABVX numbers for the 48w P2b open label maint trial are pretty remarkable. Key is using the same pt subgroup enrolled in the P3 maint trial. 77% remission in AT naive is really an imaginary number and better than SNY TL1A maint data just out. Very high confidence for P3 maint"
X Link 2026-02-17T11:20Z [---] followers, [----] engagements

"The king of Copper Robert Friedland: "We've mined [---] million tonnes since [----] BC and at the current rate we need to mine [---] million tonnes in the next [--] years alone. The demand for Copper is insane and the miners are going to hold up the whole world trying to find it.""
X Link 2026-02-17T03:10Z 48.4K followers, 64.2K engagements

"Software-as-a-service (SaaS) investors getting ready for the market to open on Tuesday"
X Link 2026-02-16T21:38Z 78.5K followers, 224K engagements

"Reviewing Claude Code output before pushing directly to prod"
X Link 2026-02-16T05:59Z 25.9K followers, 1.2M engagements

"$ABVX thank you"
X Link 2026-02-16T17:51Z [---] followers, [---] engagements

"$ABVX Betaville 'uncooked alrt'"
X Link 2026-02-12T13:25Z [---] followers, 11.8K engagements

"Arthur Mensch Mistral AI CEO: "In the US it is a big market. Their strength is they can scale quickly. We need to think of Europe as a unified market with enterprises buying European technology with states buying European technologies"
X Link 2026-02-11T17:33Z 39K followers, 61.9K engagements

"$ABVX Such low volume action but does look constructive nonetheless"
X Link 2026-02-09T20:51Z [--] followers, [---] engagements

"$AZN $ABVX reports at 6:45 AM ET tomorrow Bullish Risk Reversal executed today Sold [----] Feb $185 Puts Bought [----] March $220 Calls IF it is not LLY buy tuesday can it be AZN buying tuesday😎😂😂"
X Link 2026-02-09T17:23Z [---] followers, [----] engagements

"$600 billion in CapEx from just four companies this year (expected). QE-like spending"
X Link 2026-02-07T21:21Z 11K followers, [----] engagements

"Global chip sales hit $791.7B in [----] up 25.6% year over year. SIA expects $1 trillion in [----]. The biggest segment: advanced compute chips from Nvidia AMD and Intel at $301.9B up 40%. Memory chips second at $223.1B up 35% with prices surging from AI-driven shortages. SIA's CEO says every exec he talked to in Silicon Valley had the same message: "My orders are completely full." The AI infrastructure buildout isn't slowing down. It's accelerating into every layer of the chip stack."
X Link 2026-02-07T21:01Z 47.8K followers, 12.5K engagements

"This clown wants to make France an AI leader with 30M. [--] million to attract and support around forty top-tier international researchers. They chose France for its values and its commitment to science. Sometimes its too slow [--] billion mobilized as early as [----] to build France [----]. A France that advances health climate and fundamental science by investing boldly in artificial intelligence. Over [---] billion in private investment announced at the Paris AI Summit by French and international companies to develop AI in France. Thats it #1 In [----] France ranked first among countries attracting"
X Link 2026-02-07T14:22Z 10.3M followers, 3.4M engagements

"L'Obefazimod mdicament convoit par les USA 💊 "a permet de rduire les cytokines pro-inflammatoires ; il y en a plusieurs qui sont rduites dans cette maladie et qui vont baisser." 💬 Marc de Garidel directeur gnral d'Abivax"
X Link 2026-02-05T07:31Z 342.5K followers, 12.6K engagements

"RT @chigrl: US Yield Curve Nears Widest in Four Years A key part of the US yield curve is near its steepest level in four years as investo"
X Link 2026-02-04T19:39Z [---] followers, [--] engagements

"US Yield Curve Nears Widest in Four Years A key part of the US yield curve is near its steepest level in four years as investors look to the Treasurys quarterly bond sale plans later Wednesday for clues on future government issuance. The difference between two- and ten-year Treasury yields is currently around [--] basis points closing in on a four-year high of [--] reached in April [----]. Its climbed from a recent low of [--] basis points over the past week. (BBG) https://twitter.com/i/web/status/2019025536295502012 https://twitter.com/i/web/status/2019025536295502012"
X Link 2026-02-04T12:29Z 347.1K followers, 15.3K engagements

"Marc de Garidel has been granted [------] free shares representing 20m at current prices. $ABVX #Abivax"
X Link 2026-02-03T10:03Z [--] followers, [----] engagements

"ABIVAX Marc de Garidel Thoron a acquis des titres Abivax https://www.boursier.com/actions/actualites/news/marc-de-garidel-thoron-a-acquis-des-titres-abivax-977580.html https://www.boursier.com/actions/actualites/news/marc-de-garidel-thoron-a-acquis-des-titres-abivax-977580.html"
X Link 2026-02-03T08:34Z [---] followers, [----] engagements

"$BBIO could be the next $VRTX"
X Link 2026-01-27T21:30Z 10.9K followers, [----] engagements

Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing